Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imilecleucel-T

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Research Partnership

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

- PMLiVE

Novartis talks the talk with new MS digital tools

Presents real world terms in online dictionary and Chrome Extension

- PMLiVE

Merck forges cancer-focused big data alliance with Palantir

Plans to develop a collaborative analytics platform to accelerate research and improve outcomes

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

- PMLiVE

FDA starts speedy review of Merck/Pfizer’s PD-L1 inhibitor

If approved avelumab would be first approved cancer immunotherapy for metastatic MCC

- PMLiVE

GSK tops Access to Medicines Index for fifth time running

Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag

- PMLiVE

Merck’s pharma unit faces tougher 2017 as fertility boost recedes

Looks to new products to drive growth as fertility drug rivals return to market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links